Sensor-Augmented Pump Therapy for A1C Reduction (STAR 3) Study
Results from the 6-month continuation phase
- Richard M. Bergenstal, MD1⇓,
- William V. Tamborlane, MD2,
- Andrew Ahmann, MD3,
- John B. Buse, MD, PHD4,
- George Dailey, MD5,
- Stephen N. Davis, MD6,
- Carol Joyce, MD7,
- Bruce A. Perkins, MD8,
- John B. Welsh, MD, PHD9,
- Steven M. Willi, MD10,
- Michael A. Wood, MD11 and
- for the STAR 3 Study Group*
- 1International Diabetes Center at Park Nicollet, Minneapolis, Minnesota
- 2Yale University, New Haven, Connecticut
- 3Oregon Health and Science University, Portland, Oregon
- 4University of North Carolina School of Medicine, Chapel Hill, North Carolina
- 5Scripps Institute, La Jolla, California
- 6University of Maryland School of Medicine, Baltimore, Maryland
- 7Memorial University of Newfoundland, St. John’s Health Science Centre, St. Johns’s, Newfoundland and Labrador, Canada
- 8Toronto General Hospital, Toronto, Ontario, Canada
- 9Medtronic, Inc., Northridge, California
- 10Children’s Hospital of Philadelphia, Philadelphia, Pennsylvania
- 11Helen DeVos Children’s Hospital, Grand Rapids, Michigan
- Corresponding author: Richard M. Bergenstal, .
OBJECTIVE To examine the effects of crossing over from optimized multiple daily injection (MDI) therapy to sensor-augmented pump (SAP) therapy for 6 months, and the effects of 18 months’ sustained use of SAP.
RESEARCH DESIGN AND METHODS The 6-month, single-crossover continuation phase of Sensor-Augmented Pump Therapy for A1C Reduction (STAR 3) provided SAP therapy to 420 subjects who completed the 1-year randomized study. The primary outcome was change in A1C in the crossover group.
RESULTS A1C values were initially lower in the continuing-SAP group than in the crossover group (7.4 vs. 8.0%, P < 0.001). A1C values remained reduced in the SAP group. After 3 months on the SAP system, A1C decreased to 7.6% in the crossover group (P < 0.001); this was a significant and sustained decrease among both adults and children (P < 0.05).
CONCLUSIONS Switching from optimized MDI to SAP therapy allowed for rapid and safe A1C reductions. Glycemic benefits of SAP therapy persist for at least 18 months.
- Received June 30, 2011.
- Accepted August 24, 2011.
- © 2011 by the American Diabetes Association.
Readers may use this article as long as the work is properly cited, the use is educational and not for profit, and the work is not altered. See http://creativecommons.org/licenses/by-nc-nd/3.0/ for details.